PubMed Health⌕ Search

Biomedical subjects

Jon Salmanton-García

Publications and source records attributed to Jon Salmanton-García.

2 recordsLinked to original sources
PubMed2026

Global reach and sustained engagement of a structured digital education program in medical mycology: an observational analysis of the 2025 ESCMID-EFISG webinar series.

OBJECTIVES: Evaluate the 2025 European Society of Clinical Microbiology and Infectious Diseases-European Fungal Infection Study Group webinar series to assess digital education as a scalable, equitable model for global professional development in medical mycology. METHODS: This observational study analyzed Zoom metadata across 17 webinars (January-December 2025). Metrics included registration, unique viewers, peak concurrent views, attendance rate, and duration. RESULTS: The series recorded 4631 registrations and 1372 unique participants. Median live attendance was 199 (interquartile range [IQR] 138-269), with a 39.3% attendance rate (IQR 33.7-47.5%) and peak concurrent viewership of 165 (IQR 106-229). Median session duration was 108 minutes. Webinars engaged a median of 60 countries (range 26-89) simultaneously, spanning 128 countries globally. Faculty comprised 67 unique experts from 23 countries with balanced gender representation (52.8% men, 47.2% women), of whom 16.4% (n = 11/67) were affiliated with institutions in low- and middle-income countries. CONCLUSION: Structured digital programs achieve wide global reach and sustained engagement. Strong participation in long-form sessions supports implementing Continuing Medical Education accreditation and unrestricted on-demand access to enhance global health equity.

Antimicrobial resistance↗
PubMed2025

Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM.

Candida species are the predominant cause of fungal infections in patients treated in hospital, contributing substantially to morbidity and mortality. Candidaemia and other forms of invasive candidiasis primarily affect patients who are immunocompromised or critically ill. In contrast, mucocutaneous forms of candidiasis, such as oral thrush and vulvovaginal candidiasis, can occur in otherwise healthy individuals. Although mucocutaneous candidiasis is generally not life-threatening, it can cause considerable discomfort, recurrent infections, and complications, particularly in patients with underlying conditions such as diabetes or in those taking immunosuppressive therapies. The rise of difficult-to-treat Candida infections is driven by new host factors and antifungal resistance. Pathogens, such as Candida auris (Candidozyma auris) and fluconazole-resistant Candida parapsilosis, pose serious global health risks. Recent taxonomic revisions have reclassified several Candida spp, potentially causing confusion in clinical practice. Current management guidelines are limited in scope, with poor coverage of emerging pathogens and new treatment options. In this Review, we provide updated recommendations for managing Candida infections, with detailed evidence summaries available in the appendix.

Humans↗